x min read

Momentum Stocks: Quest Diagnostics Inc. (NYSE:DGX), Alcoa Inc. (NYSE:AA), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Catamaran Corporation (NASDAQ:CTRX), Repligen Corporation (NASDAQ:RGEN)

Momentum Stocks: Quest Diagnostics Inc. (NYSE:DGX), Alcoa Inc. (NYSE:AA), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Catamaran Corporation (NASDAQ:CTRX), Repligen Corporation (NASDAQ:RGEN)
Written by
Charles Donlon
Published on
November 5, 2014
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook
InsidrFinancial

Quest Diagnostics (NYSE:DGX) announced BRCAvantage Plus, the company's first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non-BRCA as well as BRCA genes. The new service is now available in all 50 states. Quest Diagnostics Inc. (NYSE:DGX) belongs to Healthcare sector. Its net profit margin is 6.90% and weekly performance is -3.73%. On last trading day company shares ended up $61.36. Quest Diagnostics Inc. (NYSE:DGX) distance from 50-day simple moving average (SMA50) is -0.29%. Alcoa Inc. (NYSE:AA) is investing $190 million at its Davenport Works, IA, plant which will enable it to beef up its product range for aerospace and industrial markets. The investment will be made to install new manufacturing technology, enabling the plant to make the biggest high-strength monolithic wing ribs in the industry. Alcoa Inc. (NYSE:AA) shares moved down -2.19% in last trading session and ended the day at $16.56. AA Gross Margin is 18.40% and its return on assets is -6.70%. Alcoa Inc. (NYSE:AA) quarterly performance is 0.73%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Nov. 3 reported a third-quarter loss of $10.7 million. The company had a loss of 5 cents per share. The average estimate of analysts was for a loss of 13 cents per share. ARNA posted revenue of $8.2 million in the period, which did not meet Street forecasts. Analysts expected $9.8 million. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s stock on 04 November traded at beginning with a price of $4.21 and when day-trade ended the stock finally advanced 2.13% to end at $4.31. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)'s showed weekly performance of -0.92%. Catamaran Corp (NASDAQ:CTRX) last released its earnings data on Thursday, October 30th. The company reported $0.58 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.56 by $0.02. The company had revenue of $5.50 billion for the quarter, compared to the consensus estimate of $5.36 billion. During the same quarter in the prior year, the company posted $0.52 earnings per share. The company’s quarterly revenue was up 53.3% on a year-over-year basis. Analysts expect that Catamaran Corp will post $2.23 EPS for the current fiscal year. Catamaran Corporation (NASDAQ:CTRX) ended the last trading day at $47.29. Company weekly volatility is calculated as 3.30% and price to cash ratio as 13.83. Catamaran Corporation (NASDAQ:CTRX) showed a weekly performance of 10.70%. Repligen Corp. (NASDAQ:RGEN) last issued its quarterly earnings data on Monday, August 11th. The company reported $0.09 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.06 by $0.03. The company had revenue of $15.60 million for the quarter, compared to the consensus estimate of $14.90 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s quarterly revenue was down 10.9% on a year-over-year basis. On average, analysts predict that Repligen will post $0.28 earnings per share for the current fiscal year. Repligen Corporation (NASDAQ:RGEN) shares moved down -1.37% in last trading session and ended the day at $25.11. RGEN Gross Margin is 62.50% and its return on assets is 13.60%. Repligen Corporation (NASDAQ:RGEN) quarterly performance is 16.95%.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.